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Background. No studies have evaluated the impact of multiple generic immunosuppressionmedications on transplant coordinators
(TCs) and patients. Methods. A cross-sectional, multicenter online survey of TCs managing transplant recipients’ outpatient
immunosuppression was undertaken to assess TCs’ perceptions of the impact of multiple generic immunosuppression therapies on
patients and workload. Results. Forty-six of 106 transplant centers contacted (43%) completed the survey, with usable information
from 34 TCs (53% in centers performing >100 solid organ transplants annually, 82% registered nurses, and 68% with >5-year
experience working with transplant patients). TCs indicated that “change in strength,” “switching from branded to generics,” “heavy
pill burden,” and “switching from one generic to another” were the four most frequent reasons for patient confusion regarding
immunosuppression. TCs reported increased patient confusion over the previous year for patients on generic immunosuppression
therapy: 44% answered ≥3 patient calls/day regarding confusion over immunosuppression therapy. Most TCs indicated increased
workload since the introduction of generic immunosuppression therapy. TCs perceived “acute rejection rates,” “rate of gra loss,”
and “poor patient adherence” as the three most likely consequences of multiple generic immunosuppression therapy. Conclusion.
TCs associated availability of multiple generic immunosuppression therapy with increased patient confusion and time spent
addressing patient concerns.
1. Introduction
Immunosuppression regimens containing mycophenolate
mofetil (MMF) and tacrolimus (TAC) have demonstrated
eﬀectiveness to prevent acute rejection in solid organ trans-
plant recipients [1, 2]. Furthermore, MMF and TAC are
listed as preferred agents in solid organ transplant clinical
practice guidelines such as the Kidney Disease Improving
Global Outcomes (KDIGO) [3, 4]. Since the approval of
the �rst generic MMF and TAC in July 2008 and August
of 2009, respectively, there have been 10 generic manufac-
turers of MMF and 4 generic manufacturers of TAC that
have emerged [5]. e American Society of Transplantation
(AST) supports the use of generic immunosuppressants in
transplant patients but stresses the need for bioequivalence
testing in this patient population. Furthermore, AST has
expressed caution regarding the currently unquanti�ed risk
that may be associated with switching immunosuppressive
agents under uncontrolled circumstances and the need for
clear labeling and patient education regarding any switch to
or between generic formulations [6]. e KDIGO guidelines
comment that because head-to-head data comparing eﬃcacy
and toxicity are generally not available for most generics,
caution should therefore be exercised in choosing a generic
formulation for use in kidney transplant recipients, and that
ideally, a generic formulation should be used only aer its
safety and eﬃcacy have been established in kidney transplant
patients [3].
A recent study explored the eﬀectiveness and safety
of converting transplant patients from branded Prograf
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to generic TAC [7]. e single-center, retrospective, non-
randomized study reported that renal transplant patients
experienced an average drop in the trough concentrations
of TAC by 11.9% or 0.87 ng/mL [7]. Despite the drop in
TAC concentrations, study investigators concluded that the
conversion to generic TAC appears to be safe when coupled
with “vigilant therapeutic drug monitoring” [7]. In response
to these �ndings, as well as other recent case reports [8, 9], the
transplant community continues to heighten awareness with
respect to additional concerns for use of generic immuno-
suppressants, including the lack of research on patient and
provider perspectives.
In one qualitative study in Australia, designed to obtain
consumers’ perspective on generic medicine use in general,
patients reported a considerable mistrust of generic prod-
ucts [10]. is �nding was con�rmed in a recent survey
of kidney transplant patients [11]. Although the �ndings
from the Australian study are not directly related to a
transplant population or immunosuppressants, the study
also determined that substitution of a wide array of generic
products and variability in their packaging added to con-
sumers’ overall concern, resulting in poor compliance [10].
Hesitation regarding the interchangeability of branded and
generic therapies has been well documented throughout
the literature for chronic diseases such as hypertension and
congestive heart failure [12–14]; however, no studies have
evaluated the impact of the growing availability of generic
immunosuppressive agents and the consequences that may
result for transplant coordinators and transplant patients.
Preliminary reports suggest multiple switching among
generic immunosuppressant products is occurring in practice
and oen without the knowledge of the provider [15].
Furthermore, patient confusion may be related to switches
across multiple generic immunosuppression therapies [16],
and provider workloads may increase due to recommended
“vigilant therapeutic drug monitoring” upon switching a
patient to a generic immunosuppressant [7]. erefore, this
study sought to examine transplant coordinator perspectives
on their workload, patient confusion, patient education
initiatives, and coordinators’ perception, as to whether poor
patient outcomesmay have resulted from themultiple generic
MMF and TAC therapies and the increasing complexity of
immunosuppressants on the market.
2. Methods
Anobservational, cross-sectional,multicenter studywas con-
ducted via web-based survey. From August 2010 to Septem-
ber 2010, email invitations with a link to an online survey
(see Appendix Supplementary Material available online at
http://dx.doi.org/10.1155/2013/897434) and a description of
the study were sent to transplant coordinators from a list
of 200 practice managers within 106 transplant centers. e
list of practice managers was based on convenience sampling
and determined a priori to survey development. is study
was designed to be a one-time questionnaire to view people’s
perception of workload over time. As such, the questionnaire
used is not intended to be a validated instrument.
Transplant coordinators who were able to read English
and complete an electronic web-based survey were included.
Additionally, transplant coordinators must have provided
informed consent at survey launch before initiation of sur-
vey questions. A screening question within the web-based
survey was used to exclude transplant coordinators who did
not participate directly in the management of outpatient
immunosuppression therapy. ree followup emails were
sent as reminders. No honorarium was provided for survey
completion. Further, because this study was designed based
on convenience sampling, no hypotheses were de�ned, and
no power or sample size calculations were made. Upon
completion of the survey, data was entered into a database
and analyzed using descriptive statistics.
Liberty IRB (an independent central institutional review
board) approved this study. Immunosuppression drug ther-
apy selections weremade by the clinician under conditions of
routine care and were not impacted by the study.
3. Results
3.1. General and Demographic Data. Forty-six of the 106
transplant centers contacted (43%) completed or par-
tially completed the online survey. Usable information was
obtained from 28 transplant centers, which corresponded to
34 transplant coordinators. Transplant centers were primarily
located in the south, midwest, and western regions of the
United States (US), andmore than half the centers performed
more than 100 transplants annually (Table 1). e majority
of transplant coordinators who responded to the survey were
registered nurses, and 68% had more than �ve years of
experience working with transplant patients.
3.2. Patient Confusion. Transplant coordinators reported
increased patient confusion over the past year for patients-
receiving generic MMF (50%) or generic TAC (40%). Forty-
four percent of the transplant coordinators reported that
patients ask questions regarding their immunosuppressant
therapy at every visit (Figure 1), and 18% reported that
patients request information between visits via phone (Figure
1). Additionally, transplant coordinators reported that they
answer at least three calls per day from patients (44%)
and caregivers (20%) who have confusion regarding their
immunosuppression therapy.
e surveyed sample of transplant coordinators also
indicated that three out of every four patients (76.5%) are
oen confused or sometimes confused about their immuno-
suppression therapy. e remaining ones out of every four
patients was reported to be rarely confused about their
immunosuppression. Furthermore, when askedwhat propor-
tion of their transplant patient population is at least somewhat
confused about their immunosuppression therapy, 45% of
the coordinators sampled reported that the proportion was
greater than 10% (Figure 2).
Transplant coordinators indicated that change in strength,
switching from branded to generic medications, heavy pill
burden, and switching from one generic to another generic
were the top four reasons for patient confusion regarding
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T 1: Transplant coordinator demographics.
Characteristic Transplant coordinators, 𝑛𝑛 (%)(𝑁𝑁 𝑁 𝑁𝑁)
US region
North 2 (5.9)
Midwest 6 (17.6)
West 7 (20.6)
South 19 (55.9)
Number of solid organ transplants
performed annually at transplant
center
1–25 2 (5.9)
26–50 4 (11.8)
51–75 1 (2.9)
76–100 9 (26.5)
101–200 10 (29.4)
>200 8 (23.5)
Role/title of transplant coordinator
Registered nurse 28 (82.4)
Certi�ed registered nurse
practitioner 4 (11.8)
Physician assistant 1 (2.9)
Other 1 (2.9)
Years spent working with
transplant patients
<1 year 1 (2.9)
2-3 years 3(8.8)
4-5 years 7 (20.6)
>5 years 23 (67.6)
their immunosuppression therapy. Transplant coordinators
ranked the factors contributing to patient confusion on a 5-
point scale (1 = not a contributor; 5 = main contributor).
Average scale ratings of transplant coordinator responses for
the immunosuppressant therapy-related factors contributing
to patient confusion can be located in Figure 3.
3.3. Transplant CoordinatorWorkload. emajority of trans-
plant coordinators who responded to the survey indicated an
increase in workload since the introduction of generic MMF
(62%) and TAC (65%) products. Fieen percent of transplant
coordinators reported that more than half of transplant
recipients had switched from branded to generic TAC, and
38% reported more than half of recipients switched from
branded to generic MMF (Figure 4).
Nearly one-third (29%) of transplant coordinators
reportedly spend greater than 5 hours per week on the
phone with patients discussing immunosuppressant therapy
issues (Table 2). Similarly, more than one-quarter (27%)
spend 2 hours per week on the phone with pharmacies,
and 32% reportedly spend 1 hour weekly with other
healthcare providers regarding immunosuppressant therapy
issues. With respect to clinic visits, transplant coordinators
estimated that the average duration of a patient clinic
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F 1: Frequency of patient questions regarding immunosup-
pressant therapy.
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F 2: Proportion of patients confused about immunosuppres-
sant therapy.
visit is from 30 minutes to 1 hour during the �rst year
posttransplant; 62% of coordinators reported that more than
25% of the total clinic visit time posttransplant is spent on
immunosuppressant education. e majority of transplant
coordinators reportedly work in a center with a formal
patient education plan (85%) and staﬀ training on education
programs (77%). Nearly 80% of transplant coordinators
reported that nurses are primarily responsible for staﬃng
patient education programs, and the same percentage
reported that patient education initiatives have increased in
the past year and are continuing to increase in importance.
Additionally, in the past 1, 3, and 5 years, the majority of
transplant coordinators (68%, 71%, and 62%, respectively)
reported increased time spent on educating the patient about
immunosuppressant therapy.
Aer importance of adherence (taking medications daily)
and side eﬀects, the total number of medications, heavy pill
burden, and change in pill strength were rated the factors
contributing most to the amount of education time required
to inform a transplant recipient about his/her immunosup-
pressant therapy. ese �ndings are supported by previous
literature documenting the importance of educating trans-
plant patients on the importance of adherence as a strategy
for preventing adverse consequences [17].
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T 2: Coordinator time spent on telephone regarding immunosuppressant therapy issues.
Number of hours per week
Hour(s) 0 0.5 1 1.5 2 2–5 >5
% transplant coordinators
Patients 2.9 8.8 14.7 2.9 17.6 23.5 29.4
Caregivers 5.9 26.5 14.7 8.8 17.6 14.7 11.8
Pharmacies 0.0 17.6 5.9 11.8 26.5 20.6 17.6
Other healthcare providers 14.7 11.8 32.4 14.7 8.8 11.8 5.9
Insurers/health plans 17.6 8.8 11.8 17.6 17.6 14.7 11.8
Mean rating on 5-point scale
54321
2.91
3.26
2.68
3.44
3.15
3.18
3.29
3.50
2.29
Switching from one branded treatment
to another branded treatment
Switching from one generic treatment
to another generic
Switching from generic to branded
Switching from branded to generic medications
>1 generic medication in the immunosuppressant regimen
Total number of medications in immunosuppressant regimen
Pill, color, shape and marking
Change in strength
Heavy pill burden
F 3: Immunosuppressant-related factors contributing to patient confusion.
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Transplant coordinators were also surveyed on their
knowledge of current availability of branded and generic
immunosuppressant therapies. ree out of four transplant
coordinators (76.5%) correctly identi�ed which branded
immunosuppressant therapy agents became generic over the
past year (Cellcept and Prograf). e remaining correspon-
dents (23.5%) reported knowing that there were generic
products for Myfortic and Rapamune, although these agents
are only available as branded products. Transplant coor-
dinator responses were varied regarding the number of
generics available forMMF and TAC. Transplant coordinator
confusion, with respect to the availability of generic immuno-
suppressant agents, was further demonstrated by the fact that
38% of coordinators correctly identi�ed how many di�erent
generic manufacturers of MMF were currently available,
and 9% correctly identi�ed the number of TAC generic
manufacturers (at the time of survey completion).
3.4. Interruptions in Immunosuppressant erapy. Patient
out-of-pocket amount and reimbursement price were reported
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to be the highest-ranking factors in terms of signi�cance
in the decision to substitute a generic for a branded
immunosuppressant. Only half of the transplant coordinators
reported that their transplant team had reviewed eﬃcacy
studies for generic agents since their introduction, and of
those who had, 65% answered that the studies in�uenced
prescribing patterns. For TAC and MMF, transplant coordi-
nators reported acute rejection rates, rate of gra loss, and poor
patient adherence to be the three most likely events to occur
due to the availability of multiple generic immunosuppres-
sants. (Note that each of these factors was rated 3 or higher on
a 5-point scale, with “5” being very likely. e one exception
was poor patient adherence for generic MMF, which received
a rating of 2.97.) Respondents were also asked how many
transplant patients at their center experienced adverse events
during maintenance immunosuppression therapy: 41% of
coordinators reported that 10% or fewer patients experienced
adverse events (Figure 5).
4. Discussion
Posttransplant immunosuppression therapy regimens oen
contain an antimetabolite and a calcineurin inhibitor, such
as MMF and TAC, respectively. With the recent introduction
of several generic MMF and TAC options, concerns have
been raised by patients and providers regarding the use of
generics for maintenance immunosuppression therapy. e
issues related to generic substitution can be compounded
by the impact of multiple switches between generic formu-
lations arising due to insurance coverage arrangements and
availability at any given time at the pharmacy, beyond the
control of the transplant center or the patient. us, this
study sought to examine whether transplant coordinators
feel the availability of multiple generic immunosuppressant
therapies is associated with increased patient confusion and
coordinator workload. e 34 coordinators surveyed, who
represented a total of 28 centers, indicated that transplant
recipient confusion and transplant coordinator workloads
may increase due to the availability of multiple generic
immunosuppressant therapies. ese data are supported
by previous �ndings that have linked increases in patient
confusion as a result of generic substitution to decreased
patient adherence and increased patient anxiety [14].
Although not the focus of this study, transplant coordina-
tors also provided qualitative responses to some survey ques-
tions, in which several respondents stressed the increased
workload, and time spent addressing patient concerns is
primarily related to additional time spent educating patients,
additional laboratory monitoring, and followup evaluations.
is �nding is likely attributable to guideline-suggested ther-
apeutic drug monitoring and followup visits upon changing
a patient’s calcineurin inhibitor regimen [3] and supported
by recently published data regarding the direct comparison
of branded versus generic TAC [7]. Despite increasing eﬀorts
to implement therapeutic drug monitoring for MMF into
clinical practice [18], MMF concentrations are not rou-
tinely monitored [3]. Studies have demonstrated a potential
link between mycophenolic acid concentrations, the risk of
30
20
10
5
15
25
0
C
o
o
rd
in
at
o
rs
 (
%
)
Proportion of patients at center (%)
0
Do not
know
26.5
14.7 14.7
20.6
5.9
2.9 2.9
<5 6–10 11–25 26–50 51–75 76–90 >90
F 5: Transplant coordinator-reported proportion of trans-
plant recipients experiencing adverse events during maintenance
immunosuppression therapy.
allogra rejection [18–20], and a high degree of intrapa-
tient variability of mycophenolic acid pharmacokinetics. e
introduction of several generic MMF products may therefore
further decrease the predictability of a patient’smycophenolic
acid concentrations and warrant routine therapeutic drug
monitoring, adding even more to the workload of coordi-
nators and the amount of healthcare resources consumed
in these patients. Safe and eﬀective conversion to generic
immunosuppression therapies may require additional moni-
toring and followup eﬀorts [7], resulting in the consumption
of greater healthcare resources. Additionally, it has been
estimated that the cost of a therapeutic drug and allogra
monitoringmay costmore than $750 per visit [15]. Lastly, the
burden on patients in terms of blood sampling and inconve-
niencewould be high, particularly for generic formulations of
MMF for which measurement of abbreviated area under the
curve (AUC) would be required for accurate assessment of
exposure, with possible consequences for patient compliance.
Ultimately, the perceived cost savings associated with generic
immunosuppressants may be neutralized or, at best, oﬀset by
the additional testing and procedures required upon product
switching.
Transplant coordinators also provided comments regard-
ing the coverage-related challenges associated with pro-
viding branded immunosuppression therapies to patients.
Transplant coordinators are oen responsible for obtaining
prior authorization from insurance companies for branded
immunosuppression therapy, thus increasing their workload.
Switching to generic immunosuppression therapy would
eliminate the added time of obtaining prior authorization and
may result in reduced workload for transplant coordinators.
One of the limitations of this study is that we did not ask any
questions around this topic or around the number of patients
that cannot pay for the brandedmedications due to insurance
coverage, and so forth.
We recognize that there are other limitations of the study
that merit consideration. First, it lacked the perspective of the
patient and relied upon transplant coordinators to generalize
and estimate their perceptions of their individual patient
populations. us, the transplant coordinators inferred the
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level of confusion about the immunosuppression regimen
based on their experience, and, speci�cally, the number of
phone calls they received with enquiries from patients or
caregivers but no patient-reported data on confusion was
collected. Second, fewer than half the transplant centers that
were contacted responded, with a consequent potential for
the introduction of bias in the results.ird, the study did not
include any assessment of howpatient demographics, and, for
example, level of education may have in�uenced the degree
of patient confusion. Fourth, the scope of the survey did
not permit a detailed examination of transplant coordinators’
impression of the incidence of adverse events in patients
receiving speci�c branded or generic immunosuppressive
agents. Lastly, while respondents were asked what events
they considered most likely to occur due to the availability
of multiple generic preparations of TAC and MMF, their
feedback was opinion based and not derived from events
occurring at their center.
e consensus among the transplant community is that
generic immunotherapy can provide a safe alternative to
branded drugs, but certain precautions must be followed.
Patients and transplant coordinators must be aware of the
switch to generic, the same generic drug should be adminis-
tered continuously to receive consistent bene�t, and stringent
therapeutic drug monitoring must be administered during
the initial switch phase [21]. e impact on transplant
coordinators has not previously been assessed. Although
no testing for statistical signi�cance was performed, the
key �ndings of this study are likely experienced by most,
if not all transplant centers throughout the US. Increased
awareness among transplant coordinators of the challenges
brought about by multiple generic immunosuppressants may
therefore be necessary to identify and mitigate patient care-
related issues. Additional studies will also be necessary to
address the primary limitation of this study and gain insights
directly from patients regarding generic immunosuppression
therapies. Furthermore, given the reimbursement and access
challenges that already face this patient population [22–25],
additional research is warranted to identify how minimizing
patient confusion and coordinator workload may lead to
improved outcomes.
5. Conclusion
Transplant centers must evaluate the value of multiple
generic immunosuppressive therapies in the context of chal-
lenges to transplant patients and transplant coordinators.
Increases in transplant coordinator workload, patient con-
fusion, and potential interruptions in therapy all introduce
additional risks to a population that already takes multi-
ple medications, where nonadherence could be detrimental
to gra outcomes. Furthermore, the perceived cost sav-
ings associated with generic therapies need to be balanced
with necessary therapeutic drug monitoring, and the addi-
tional health care resources needed to safely and eﬀectively
transition patients to generic immunosuppressants. Ulti-
mately, eﬀorts to optimize therapy and remove some of the
risk for poor outcomes should become a priority for all
stakeholders involved in delivery and access to posttransplant
care.
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